Evaluating Metformin for Knee Osteoarthritis
Official title: The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis
Run by Tanta University · NCT06231758 · Data updated 2026-11-12
This study is testing if Metformin can help people aged 30 to 60 with knee osteoarthritis feel better and improve their joint function compared to another medication.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 30 Years to 60 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Damietta, New Damietta) |
| Status | Recruiting |
| Started | January 30, 2024 |
| Main results expected | November 20, 2026 |
| Study ends | November 20, 2027 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT06231758 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 30 to 60 with X-ray confirmed Kellgren-Lawrence grade II or III knee osteoarthritis.
✕Probably not a fit
Patients under 30 or over 60 years old, or those with inflammatory arthritis or other significant health issues, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the safety and efficacy of Metformin in patients with knee osteoarthritis, a chronic condition that significantly impacts mobility and quality of life. Participants aged 30 to 60 with confirmed moderate to severe osteoarthritis will receive either Metformin or Celecoxib to assess improvements in symptoms and joint function. The study aims to provide insights into whether Metformin can alter the disease progression of osteoarthritis, which currently lacks effective long-term treatment options.
Why it matters
Potential benefit: If successful, this study could offer a new treatment option that may slow the progression of knee osteoarthritis and improve patient outcomes.
How similar studies have gone: While there have been studies exploring various treatments for osteoarthritis, the specific use of Metformin in this context is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary osteoarthritis Patients recruited were between 30 to 60 years of age. * X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria. Exclusion Criteria: Patients with age less than 30 years or more than 60 years Patients Presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug Patients Were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying OA of the hip of sufficient severity to interfere with the functional assessment of the knee Patients had previous or ongoing treatment with oral SYSDOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study Patients having a known hypersensitivity to the used medications Patients have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\< 10.0 g/ dl or haematocrit \< 30%). Patients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.
Where it's running
-
Mostafa Bahaa
Damietta, New Damietta, Egypt Recruiting
Study contacts
- Study coordinator: Mostafa Bahaa
- Email: mbahaa@horus.edu.eg
- Phone: +201025538337
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Arthrosamid versus steroid injections for managing knee osteoarthritis.
This trial will test whether a single Arthrosamid hydrogel injection works better than a standard steroid plus local anesthetic injection for adults with symptomatic knee osteoarthritis.
-
Platelet-rich plasma plus hyaluronic acid injections for knee osteoarthritis
We will try a single injection of platelet-rich plasma plus hyaluronic acid, platelet-rich plasma alone, or hyaluronic acid alone to see which works best for adults (40–75) with unilateral knee osteoarthritis who still have pain after conservative treatment.
-
Evaluating OA-SYS for knee osteoarthritis treatment
This study is testing a new treatment called OA-SYS using adult stem cells to see if it can help people with moderate to severe knee osteoarthritis feel better and improve their knee function.
-
Using bioceramic materials to repair bone defects
This study is testing if a new type of bioceramic implant can help people heal better from bone defects compared to a standard bone implant.
-
Comparing the effects of a vegan diet to an omnivorous diet before knee surgery
This study is testing whether a vegan diet for two weeks before knee surgery can help older adults with knee osteoarthritis build protein in their muscles and tissues better than a regular diet with meat.
-
Evaluation of the MISHA Knee System for treating knee osteoarthritis
This study is testing a new knee treatment called the MISHA Knee System to see if it helps people with knee osteoarthritis feel less pain and improve their function over five years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.